Product news

Share this article:

An FDA advisory panel voted that a long-acting, injectable form of Eli Lilly's best-selling drug, the antipsychotic olanzapine, is safe enough for use in some patients with schizophrenia. But panel members shared concerns raised by the FDA that Zyprexa LAI was associated with excessive sedation.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions